Home / Oncology (page 137)

Oncology

FDA Approves BMS’ Opdivo for Treatment of Renal Cell Carcinoma

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) injection, for intravenous use, for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.1 Today’s announcement marks the approval of the first and …

Read More »

FDA Approves Lilly’s Portrazza for Patients with Squamous NSCLC

INDIANAPOLIS, Nov. 24, 2015 /PRNewswire/ —  Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Portrazza™ (necitumumab injection for intravenous use, 800 mg/50 mL), in combination with gemcitabine and cisplatin, as the first biologic for the first-line treatment of people with …

Read More »

Roche’s Melanoma Drug Performs Well in Early-Stage Study

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced data from the pivotal coBRIM study, which showed that Cotellic (cobimetinib) in combination with Zelboraf (vemurafenib) helped people with BRAF V600E and V600K mutation-positive unresectable or metastatic melanoma live significantly longer (overall survival; OS) than with Zelboraf alone.1 Cotellic plus Zelboraf reduced …

Read More »

CytRx’ Aldoxorubicin Continues to Demonstrate Positive Clinical Activity in Mid-Stage Brain Cancer Trial

LOS ANGELES, Nov. 23, 2015 /PRNewswire/ — CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it has achieved its target enrollment of 28 patients with unresectable glioblastoma multiforme (GBM), a deadly form of brain cancer, in its Phase 2 trial with aldoxorubicin. …

Read More »

Novartis’ Skin Cancer Drug Combo Receives Full FDA Approval

EAST HANOVER, N.J., Nov. 20, 2015 /PRNewswire/ — Novartis today announced that the US Food and Drug Administration (FDA) has granted regular approval for the combination of Tafinlar® (dabrafenib) + Mekinist®(trametinib) for the treatment of patients with BRAF V600E/K mutation-positive unresectable or metastatic melanoma as detected by an FDA-approved test. …

Read More »

FDA Approves Takeda’s Multiple Myeloma Pill

Cambridge, Mass. and Osaka, Japan, November 20, 2015 – Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the U.S. Food and Drug Administration (FDA) has approved NINLARO®(ixazomib) capsules, the first and only oral proteasome inhibitor, indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple …

Read More »

Servier and Pfizer Get Rights to Cellectis CAR-T Therapy

November 19, 2015 – New York (USA) and Suresnes (France) – Cellectis (Alternext: ALCLS; Nasdaq: CLLS) and Servier today announced that they signed an amendment to their existing collaboration agreement from February 2014 especially for UCART19, a TALEN® gene-edited allogeneic Chimeric Antigen Receptor T-cell (CAR-T) immunotherapy. Under this amendment, Servier …

Read More »

Ziopharm Oncology Announces Data Highlighting Gene Therapy Approach in Glioma

BOSTON, Nov. 19, 2015 (GLOBE NEWSWIRE) — ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new cancer immunotherapies, today announced that the Company is presenting initial results from an ongoing Phase 1 dose-escalation study of Ad-RTS-hIL-12 + orally administered veledimex in recurrent or progressive glioblastoma or grade III malignant …

Read More »

Lilly and Merck Expand Immuno-Oncology Collaboration with Late-Stage NSCLC Study

INDIANAPOLIS and KENILWORTH, N.J., Nov. 19, 2015 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly’s ALIMTA® (pemetrexed for injection) …

Read More »